MBX Biosciences (MBX) investor relations material

Executive summary

• Focused on developing novel precision peptide therapies for endocrine and metabolic disorders, with lead candidates in chronic hypoparathyroidism and obesity.

• Achieved key pipeline milestones, including sustained one-year benefit data for once-weekly canvuparatide and initiation of Phase 3 trial recruitment.

• Initial Phase 1 data for MBX 4291 in obesity showed potential for once-monthly dosing and notable weight loss; further data expected in Q4 2026.

• Expanded obesity pipeline with nomination of MBX 6180 and MBX 5765, both designed for once-monthly dosing.

• Announced leadership transition in July 2026, with Steven Hoerter as CEO and John Smither as CFO.

Financial highlights

• Net loss for Q2 2026 was $37.1 million, compared to $19.4 million in Q2 2025; six-month net loss was $60.6 million, up from $43.3 million year-over-year.

• Operating expenses for Q2 2026 were $40.9 million, up from $21.8 million in Q2 2025, driven by increased R&D and G&A costs.

• Cash, cash equivalents, and marketable securities totaled $418.6 million as of June 30, 2026, expected to fund operations into 2029.

• R&D expenses for Q2 2026 were $31.0 million, up from $17.7 million year-over-year, mainly due to clinical trial and preclinical activity.

• G&A expenses for Q2 2026 were $9.9 million, up from $4.1 million year-over-year, reflecting higher headcount and infrastructure investments.

Outlook and guidance

• Existing cash and marketable securities expected to fund operations into 2029.

• Phase 3 pivotal trial for canvuparatide in chronic hypoparathyroidism initiated in Q3 2026, with patient recruitment underway.

• 12-week MAD (Part C) data for MBX 4291 expected in Q4 2026.

• Preclinical data for MBX 6180 to be presented in Q4 2026; IND-enabling studies ongoing for MBX 6180 and MBX 5765.

• Anticipates increased expenses as clinical programs advance and company transitions toward commercialization.